Hot Paths

Biohaven stock rises on cancer therapy data (BHVN:NYSE)

Cancer cells on human tissue. 3D illustration.

anusorn nakdee

Biohaven (BHVN) shares rose on Thursday after the company announced early-stage trial data for its cancer candidate BHV-1530 and disclosed its plans to advance the antibody-drug conjugate in a pivotal trial as early as next year.

Based on an Oct. 19

Exit mobile version